CN107011341A - 1H‑吡咯并[2,3‑b]吡啶衍生物及它们作为激酶抑制剂的用途 - Google Patents

1H‑吡咯并[2,3‑b]吡啶衍生物及它们作为激酶抑制剂的用途 Download PDF

Info

Publication number
CN107011341A
CN107011341A CN201610920724.7A CN201610920724A CN107011341A CN 107011341 A CN107011341 A CN 107011341A CN 201610920724 A CN201610920724 A CN 201610920724A CN 107011341 A CN107011341 A CN 107011341A
Authority
CN
China
Prior art keywords
pyrrolo
pyrazole
pyridin
benzyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610920724.7A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·斯托克斯
克里斯多佛·约翰·格雷厄姆
斯图亚特·克里斯多佛·雷
艾玛·杰妮·斯蒂芬尼亚克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Werneris R&d Co ltd
Original Assignee
Werneris R&d Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werneris R&d Co ltd filed Critical Werneris R&d Co ltd
Publication of CN107011341A publication Critical patent/CN107011341A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201610920724.7A 2012-01-30 2013-01-30 1H‑吡咯并[2,3‑b]吡啶衍生物及它们作为激酶抑制剂的用途 Pending CN107011341A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1201566.5 2012-01-30
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
CN201380014717.5A CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380014717.5A Division CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Publications (1)

Publication Number Publication Date
CN107011341A true CN107011341A (zh) 2017-08-04

Family

ID=45876325

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201610920724.7A Pending CN107011341A (zh) 2012-01-30 2013-01-30 1H‑吡咯并[2,3‑b]吡啶衍生物及它们作为激酶抑制剂的用途
CN201610920720.9A Expired - Fee Related CN106866658B (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN202010405942.3A Pending CN111484493A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN201380014717.5A Pending CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201610920720.9A Expired - Fee Related CN106866658B (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN202010405942.3A Pending CN111484493A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
CN201380014717.5A Pending CN104203948A (zh) 2012-01-30 2013-01-30 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Country Status (21)

Country Link
US (3) US10000481B2 (https=)
EP (1) EP2809670B1 (https=)
JP (1) JP6199316B2 (https=)
CN (4) CN107011341A (https=)
AU (1) AU2013213954B2 (https=)
BR (1) BR112014018795B1 (https=)
CA (1) CA2862940C (https=)
DK (1) DK2809670T3 (https=)
EA (1) EA026657B1 (https=)
ES (1) ES2637340T3 (https=)
GB (1) GB201201566D0 (https=)
HK (1) HK1200447A1 (https=)
HU (1) HUE035332T2 (https=)
IL (1) IL233595B (https=)
IN (1) IN2014DN06104A (https=)
MX (1) MX352927B (https=)
NZ (1) NZ627361A (https=)
PL (1) PL2809670T3 (https=)
PT (1) PT2809670T (https=)
WO (1) WO2013114113A1 (https=)
ZA (1) ZA201405070B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484493A (zh) * 2012-01-30 2020-08-04 沃纳利斯(R&D)有限公司 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406818VA (en) * 2012-04-23 2014-11-27 Genentech Inc Intermediates and processes for preparing compounds
CN105705499B (zh) * 2013-08-22 2018-10-12 基因泰克公司 用于制备化合物的方法
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
CA3015484C (en) 2016-02-23 2022-11-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
EP3674325A4 (en) 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ifm Due有限公司 用於治療與sting活性相關之病況的化合物及組合物
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
US12428395B2 (en) 2019-08-01 2025-09-30 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
JP2023540674A (ja) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
PY2157405A (es) * 2020-07-15 2022-04-22 Ifm Due Inc Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
CN118613473A (zh) * 2022-01-12 2024-09-06 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887A (zh) * 2008-01-08 2011-01-26 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102089307A (zh) * 2008-05-13 2011-06-08 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102119162A (zh) * 2008-06-11 2011-07-06 健泰科生物技术公司 二氮杂咔唑及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
DK2294065T3 (da) * 2008-01-22 2014-04-28 Vernalis R&D Ltd Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet
CN102573994B (zh) * 2009-08-06 2015-06-24 默克专利有限公司 双环脲化合物
US9290499B2 (en) * 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887A (zh) * 2008-01-08 2011-01-26 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102089307A (zh) * 2008-05-13 2011-06-08 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN102119162A (zh) * 2008-06-11 2011-07-06 健泰科生物技术公司 二氮杂咔唑及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484493A (zh) * 2012-01-30 2020-08-04 沃纳利斯(R&D)有限公司 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途

Also Published As

Publication number Publication date
MX352927B (es) 2017-12-14
BR112014018795B1 (pt) 2020-09-29
CN104203948A (zh) 2014-12-10
US10889582B2 (en) 2021-01-12
HUE035332T2 (en) 2018-05-02
PL2809670T3 (pl) 2017-10-31
EA201491376A1 (ru) 2015-01-30
US20210206762A1 (en) 2021-07-08
CA2862940C (en) 2021-09-14
CN106866658A (zh) 2017-06-20
ES2637340T3 (es) 2017-10-11
DK2809670T3 (en) 2017-08-28
IN2014DN06104A (https=) 2015-08-14
MX2014009112A (es) 2014-11-10
CA2862940A1 (en) 2013-08-08
AU2013213954B2 (en) 2016-02-25
EP2809670A1 (en) 2014-12-10
AU2013213954A1 (en) 2014-08-07
EP2809670B1 (en) 2017-05-17
EA026657B1 (ru) 2017-05-31
PT2809670T (pt) 2017-08-23
JP2015505555A (ja) 2015-02-23
WO2013114113A1 (en) 2013-08-08
JP6199316B2 (ja) 2017-09-20
IL233595A0 (en) 2014-08-31
HK1200447A1 (en) 2015-08-07
IL233595B (en) 2018-05-31
BR112014018795A2 (pt) 2017-07-04
NZ627361A (en) 2016-07-29
CN111484493A (zh) 2020-08-04
US10000481B2 (en) 2018-06-19
CN106866658B (zh) 2021-04-27
US20180362526A1 (en) 2018-12-20
GB201201566D0 (en) 2012-03-14
US20150011533A1 (en) 2015-01-08
ZA201405070B (en) 2016-03-30

Similar Documents

Publication Publication Date Title
CN106866658B (zh) 1H-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
US20250127903A1 (en) Substituted piperidine degronimers for target protein degradation
CN112166114B (zh) Brm靶向化合物和相关使用方法
CN114787159B (zh) Brm靶向化合物及相关使用方法
CN115835908A (zh) 作为fgfr抑制剂的双环杂环
CN108699032A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
CN109970743A (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
EA019785B1 (ru) Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение
MX2014013734A (es) Inhibidores de nampt.
CN107848971B (zh) 杂环化合物
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240217B (zh) 1h-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
HK1240217A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240227A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK40010369A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
HK40010369B (zh) 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
CN121974842A (en) Amine linked C for target protein degradation3Glutarimide degradation determinants
HK1233621A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240227

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170804

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1240227

Country of ref document: HK